In this study, gamma dose rates generated from the naturally occurring radioactive materials (NORM) were measured in the waste streams of a large scale and sludge onshore petroleum operations. Measurements conducted in this work involved: sludge recovery from separation tanks, sludge forming, NORM storage, scaling in oil tubulars, scaling in gas production and sedimentation in produced water evaporation ponds. Field work was carried out in many places of different terrain of an operation oil exploration and production in Murzuq basin in the Southwest of Libya. The radiation dose rates were measured using portable InSpector-1000. A total of 400 dose rates were acquired. The highest dose rate was 70 μSv/h acquired in sludge stored in barrels. The estimated mean annual equivalent doses in this field were in the range of 0.2-2.8 mSv/y in the first scenario, while in the second scenario the calculated mean annual equivalent doses were in the range of 0.04-0.68 mSv/y. It is assumed that workers may face various exposures in the field where measurements took place, considering the total annual effective dose to be 1.53 mSv/y. The main radioisotopes detected in these samples indicated by the display of the measuring device were Ra and Ra but detecting both radioisotopes in the same run is not achievable by using the display of the screen.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.apradiso.2024.111246 | DOI Listing |
Radiother Oncol
January 2025
The Royal Marsden NHS Foundation Trust, Sutton, UK; The Institute of Cancer Research, Sutton, UK.
Background: While SBRT to NSBM has become common, particularly in the oligometastatic population, the approach to treating non-spine bone metastases (NSBM) with stereotactic body radiotherapy (SBRT) varies widely across institutions and clinical trial protocols. We present a comprehensive systematic review of the literatures to inform practice recommendations on behalf of the International Stereotactic Radiosurgery Society (ISRS).
Methods: A systematic literature review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Int J Radiat Oncol Biol Phys
January 2025
Montefiore Einstein Comprehensive Cancer Center, Bronx, NY.
Background: Standard radiotherapy (RT) for locally advanced NSCLC (LA-NSCLC) employs a uniform dose of approximately 60 Gy. Recent trials demonstrated that radiotherapy dose escalation may not improve outcomes and may cause added toxicity. XXX previously performed a single-arm trial testing a personalized, risk-adapted, and de-intensified RT strategy.
View Article and Find Full Text PDFInt J Radiat Oncol Biol Phys
January 2025
Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, Texas, USA. Electronic address:
Purpose: Proton FLASH has been investigated using cyclotron and synchrocyclotron beamlines but not synchrotron beamlines. We evaluated the impact of dose rate (ultra-high [UHDR] vs. conventional [CONV]) and beam configuration (shoot-through [ST] vs.
View Article and Find Full Text PDFSeizure
January 2025
Royal Brisbane and Women's Hospital and School of Medicine and Biomedical Science, University of Queensland, Brisbane, QLD, 4027, Australia. Electronic address:
Aim: To assess whether lamotrigine (Lamictal), when used in antiseizure medication (ASM) monotherapy, is a teratogen.
Materials/methods: Analysis of data from 490 LTG monotherapy treated pregnancies and 214 pregnancies in women with epilepsy not exposed to any antiseizure medications during at least the first half of pregnancy.
Results: The LTG-treated and the untreated pregnancies were well matched in nearly all regards apart from ASM exposure.
Rheumatology (Oxford)
January 2025
Nephrology Center and Department of Rheumatology, Toranomon Hospital, Tokyo, Japan.
Objectives: To evaluate the efficacy and safety of first-line targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs) in patients with rheumatoid arthritis (RA) and chronic kidney disease (CKD).
Methods: This retrospective cohort study included 216 patients with RA prescribed their first tsDMARDs at two hospitals between 2013 and 2022. Dose reduction and contraindication guidelines for tsDMARDs according to kidney function were followed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!